Well said Dr Nichols and this could perhaps summarize the entire estradiol discussion. I will say, however, from my experience of treating over 10 thousand patients I have seen my fair share who unfortunately do have symptoms and respond favorably to CONSERVATIVE aromatase inhibition. Many of these can even be somewhat predicted, albeit not with 100% accuracy (most notably obese patients, those with very high baseline E:T ratios, and those with baseline low SHBG). You did note that you treat (or would treat) when symptoms are present, which I feel puts you on the right side of the fence on that one for sure.
On the topic of possible longterm risks of elevated E2 in males, as we all know there is not strong data one way or the other. I'll post below a couple study links that I mentioned on the forum a few days ago on a different thread regarding E2 and Carotid IMT. What I found interesting about the first study was that they did NOT administer oral estradiol (which you rightly pointed out previously would provide useless comparisons as ORAL estrogens, synthetic or bioidentical, can increase coagulability independent of actual E2 levels)...they administered parenteral estradiol which means that the data should hold true for actual serum E2 levels as opposed to the route of delivery. Your input and alternative views are welcome and appreciated as they contribute to scholarly discussion. Curious if you are a follower or mentee of Dr Neal Rouzier? Your position on some of these topics are very similar. The copy/paste from the other thread is below. All the best.
"There are no valid studies of safety/risks of elevated E2 levels for men ON TRT with upper physiologic range T levels, so we do the best with the info we have. There are a few studies (not men on TRT mind you) that did suggest a possible trend in increased carotid atherosclerosis (increased IMT as an indicator for increased cardiovascular disease) with increases in FREE estradiol levels. "
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2006-0932
http://circ.ahajournals.org/content/109/17/2074.long#sec-7
Just noticed the link for the parenteral estradiol study was broken, so I've included citation below.
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Randomized controlled trial
Hedlund PO, et al. Scand J Urol Nephrol. 2008.[/QUOT
Thanks so much for the post hopefully I can continue the conversion and further the debate. In addition to treating men, I treat just as many women on a daily basis so I am dealing with PCOS, peri menopause, menopause, and young post hysterectomy patients. Quite franklin, us men go through nothing compared to these poor women. Imagine if we were all castrated and no one would help us.
With regard to some of your points. I agree that men with high baseline E2 have been should to have a high I cide ce of cardiovascular disease. Makes perfect sense. If you look at the BMI and other risks factors in these me you see exactly
why they have cardiovascular disease. The high E2 is just a bystander and not responsible for their cardiovascular disease but a result of the obesity. It's the obesity and other conditions that kill them (HTN, CAD, dyslipidemia, etc..) but estrogen gets blamed.
Unfortunately, you do not see the cardioprotective effects of E2 unless it is given orally. IM estradurin is not oral estradiol and you could fully predict that it would not provide the cardioprotective effects that oral E2 does. It is the first pass effect that provides the cardioprotective benefits of oral estradiol. The NIH and all major European studies now use for the most part only oral estradiol as that is the only way to get all the benefits of estrogen. No RCT to date has shown oral estradiol to cause a increase in heart attacks, strokes, or DVTs. Mechanism of delivery is especially important with E2. Are we to ignore all the studies since the WHI (Premarin not E2) including the JAMA, EPAT, CORA, WEST, KEEPS, and DANISH trials with oral E2. So you point out that oral (synthetic or bioidentical) can increase coaguability, but the actual studies show now increase in adverse events with oral E2. I women greater than 60'years of age or greater than 10 years out of menopause when given Premarin (CEE) there were 30 additional adverse events out of 30,000 women. In women younger than 60 years of age even Premarin was cardioprotective. None of the adverse effects seen with Premarin have been seen with oral estradiol to date. So if oral estradiol causes a increase in coaguability leading to adverse events such as DVTs etc...the please provide me with that study and I will absolutely change my opinion.
You can't extrapolate the effects of Premarin or IM Estradurin to oral estradiol. Look at the interventional studies as listed above and see what actually happens when you give oral estradiol. Don't assume all estrogens are the same or even the effects based on mechanism of delivery are the same. Look at what happens when they are give. I can bring a womans blood levels of estrogen up with various forms of estrogen but based on the literature I strongly disagree that blood levels only are what matters. It is obtaining the proper blood levels using the right dosage, right estrogen E2, and proper route of delivery (oral) to achieve proper protection.
With regard to AIs I would definitely treat if a patient presented with symptoms of excess. I am so fortunate I guess That we just don't see it with how the T is administered in our practice.
With regard to no long term studies on increased E2 in males, I have to respectfully disagree. We have been raising men's E2 (H/Hct as well) with IM testosterone for over 50 years. Think about it. For over half a century we have been increasing E2 with T and have not seen any increase in cardiovascular mortality. In fact, we see improvement. How do we just ignore the last 50 years of T studies?
You do have studies that show the harm in blocking estrogen in men (NEJM). I have to see patients now but I would love to continue this conversion by providing some actual patient labs and their symptoms and asking you and our colleagues what they would do with "the lab values" in these men and how they would treat.
A